On Monday, July 13, the Institute for Gene Therapies (IGT) held a conversation with recognized experts on the CMS proposed rule that makes changes to the Medicaid Drug Rebate Program (MDRP) to facilitate value-based purchasing (VBP) arrangements.
Stuart Portman, Health Policy Advisor, U.S. Senate Finance Committee
Mark Trusheim, Strategic Director, MIT NEWDIGS
Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases
Thomas Evegan, VP, Integrichain
Lauren Randall Buckley, Director of Health Policy & Advocacy, IGT
View the full discussion below: